Testing a new intervention to support people who are dependent on opiate and benzodiazepine drugs

Not Applicable

Completed

Conditions: High-risk illicit drug use
Mental and Behavioural Disorders

Registration Number: ISRCTN95130898

Lead Sponsor: niversity of Stirling

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 39

Inclusion Criteria

1. People in NHS drug treatment services who have achieved a stable dose of ORT (methadone or buprenorphine)
2. Have the capacity to provide informed consent
3. Experiencing ongoing risk of harm from street benzodiazepine use. ‘Risk of harm’ was defined as: an overdose event in the last 6 months in which a street benzodiazepine was implicated (from toxicology or clinical profile) and/or persistent self-report of daily street benzo use that is confirmed by toxicology screening and/or self-report of regular use of high doses/quantities of street benzodiazepines

Exclusion Criteria

1. Co-occurring harmful alcohol use
2. Co-occurring harmful stimulant use
3. Pregnancy
4. Participation in any other research study
5. Diagnosed serious mental illness or severe cognitive impairment that clinical staff consider poses a risk to safety (of patient or staff)
6. Non-English speaking
7. People who do not have the capacity to provide informed consent
8. ‘Harmful’ alcohol or stimulant use was use at a level in which it was the dominant problem for that individual

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
se of illicit benzodiazepines measured using self-report and oral fluid testing monthly during the study

Secondary Outcome Measures

Name	Time	Method
1. Cognitive ability assessed using Addenbrooke's Cognitive Evaluation (ACE III) at baseline & follow-up (6 months)<br>2. Quality of life assessed using EQ5D-5L monthly during the study<br>3. Anxiety assessed using General Anxiety Disorder (GAD-7) at baseline & follow-up (6 months)<br>4. Depression assessed using Patient Health Questionnaire-9 (PHQ-9) at baseline & follow-up (6 months)<br>5. Self-assessed substance use recovery assessed using SURE questionnaire at baseline & follow-up (6 months)<br>6. Economic evaluation using NHS service use questionnaire completed monthly during the study<br>7. Satisfaction with professional care assessed using Consultation and Relational Empathy Measure (CARE) at follow-up (6 months)